BitFrontier Capital Holdings Engages Wellfleet Investments for Strategic Capital Raise
TL;DR
BFCH partners with Wellfleet Investments to secure funding for acquisitions and uplisting, creating potential asymmetric returns for shareholders in a disciplined turnaround.
BFCH's two-phase capital raise involves a $150k seed for compliance and a $1.5M-$2M institutional round to scale assets after OTCQB uplisting.
This strategic funding supports BFCH's focus on cognitive health and functional wellness, aiming to improve mental and physical well-being through innovation.
A physician-led public company engages a veteran investment banker to fund its turnaround and expansion into cognitive health products.
Found this article helpful?
Share it with your network and spread the knowledge!
BitFrontier Capital Holdings, Inc. (OTCID: BFCH), operating as EVERMIND Holdings, Inc., has engaged Wellfleet Investments LLC to lead its strategic capital formation efforts. Wellfleet Investments, established in New York in 1998, is a registered broker-dealer with the U.S. Securities and Exchange Commission and maintains membership with FINRA and SIPC. The firm specializes in structuring and placing financings for both private and public companies, leveraging deep relationships with family offices and institutional investors.
The capital strategy will unfold in two distinct phases. Phase I involves a seed raise of $150,000 to fund legal and compliance reviews, modernization of the Company's Charter and Bylaws, governance enhancements, and the formation of EVERMIND Labs. Proceeds will also support the finalization of the acquisition of ERApeutics, doing business as EVERMIND™ Beverage, along with PCAOB audit preparation, OTCQB uplisting readiness, and expanded investor relations. Additional information about Wellfleet and its registered principals can be accessed through FINRA BrokerCheck and the firm's official website at Wellfleet Investments.
Phase II entails an institutional raise targeting $1.5 million to $2 million, contingent upon the successful completion of Phase I and advancement to OTCQB. This subsequent funding will be utilized to vend in additional accretive assets, transition these assets into value-producing operations, and further scale the platform. Dr. Jordan P. Balencic, CEO of BFCH, emphasized the rarity of securing a FINRA-registered investment banker at this stage, noting that it validates the company's methodical approach to creating asymmetric returns for shareholders through disciplined turnaround strategies.
Jeffrey Bega, CEO and Managing Partner of Wellfleet Investments LLC, highlighted BFCH's execution of governance reset, audit readiness, and asset strategy as key factors attracting smart capital. Wellfleet's role will involve connecting BFCH's disciplined plan with family offices and institutional investors who value early-stage structured turnarounds. In parallel with these capital formation steps, BFCH has amended its Q2 Report and 2024 Management Certification on OTC Markets to ensure filings accurately reflect current management, capitalization, and strategic direction.
This engagement represents a significant development for investors and the OTC markets, as it demonstrates institutional validation of BFCH's turnaround strategy. The partnership with an established investment banking firm could enhance credibility and access to capital, potentially influencing other OTC companies to pursue similar compliance-focused approaches. For the cognitive health and functional wellness industry, the successful execution of this capital raise could accelerate the development and scaling of innovative products under the EVERMIND brand, contributing to broader market growth and investor confidence in disciplined public company turnarounds.
Curated from NewMediaWire
